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Background: The lifetime incidence of kidney stones is about two times greater in men compared to women.
Extracellular vesicles (EVs) shed from activated cells are present in the urine and may reflect or even mediate renal
physiology and/or pathology. This study was designed to standardize methodology to characterize urinary EVs by
digital flow cytometry and to identify possible sex differences in EVs in persons with and without their first
symptomatic kidney stones.
Methods: Twenty-four-hour urine collections were obtained from persons presenting with their first kidney stone
episode (n = 50 women, 60 men; age 19–76 years) and sex- and age-matched controls from the general population
(n = 24 women, 36 men).
Results: Standardization: Size of EV was variable within all groups. EV positivity was verified with two fluorophores
for surface phosphatidylserine and/or using two different protein markers specific for renal-specific cells. The
number of phosphatidylserine- and exosome marker-positive EVs did not correlate with urine osmolality and were
similar in fresh vs. frozen and between two sequential urine collections from the same individual. Sex differences:
Urine from women controls contained greater (P < 0.05) numbers of EVs positive for phosphatidylserine, exosomes,
inflammatory factors and adhesion molecules, and cell-specific markers from different segments of the nephron,
renal pelvis, and bladder compared to control men. In contrast, urine from women with kidney stones contained
significantly (P < 0.05) lower numbers of EVs derived from podocytes, parietal cells, proximal convoluted tubule, thin
and thick loop of Henle, distal tubule, collecting duct, renal pelvis, and bladder compared to control women and
contained similar quantities of these types of EVs in men with and without kidney stones. There were also no sex
differences in EVs positive for cell adhesion (E-cadherin and inter-cellular adhesion molecule-1 [ICAM-1]) molecules.
Conclusions: Unlike women who do not have kidney stones, EVs in urine from women with nephrolithiasis are
similar to men with and without kidney stones. Thus, EVs may mediate or reflect aspects of kidney stone
pathogenesis and perhaps provide clues regarding sex differences in kidney stone incidence rates.
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Approximately 10–12% of the general population is
afflicted with at least one kidney stone in their lifetime
[1], and the incidence appears to be rising in the USA
and Europe [2,3]. The lifetime incidence of kidney stone
disease is greater in men (12%) compared to women
(5%), although kidney stone incidence rises in women
after menopause [4,5]. Multiple factors contribute to
kidney stone risk including age, sex, diet, geography, and
genetic factors [2,6-8].
The majority (70–80%) of stones are composed of
calcium oxalate (CaOx), often admixed with calcium
phosphate. Changes in urine composition resulting in
supersaturation of the urine are associated with a higher
risk of developing a CaOx kidney stone. However, the
exact series of events that connect super-saturation to
formation of a kidney stone remain unclear. Thus, these
stones are often referred to as “idiopathic” calcium oxal-
ate stones. Furthermore, men are more likely to have a
calcium oxalate or uric acid stone, while women are
more likely to have a hydroxyapatite or struvite stone
[9]. The cellular and molecular factors contributing to
these sex differences in kidney stone risk are incom-
pletely understood. Some studies support a role for renal
tubular cell injury in the pathophysiology of nephro-
lithiasis [10-12]. For example, renal cells are injured by
increased urinary concentrations of lithogenic moleculesFigure 1 Biogenesis of EVs (~0.1–1 μm in size; microvesicles from plasm
body) from cells during physiological and pathological condition. Abbre
phosphatidylserine, PE phosphatidylethanolamine.(e.g., oxalate) or calcium-containing crystals [12]. Injured
and activated cells shed distinct populations of biologic-
ally active extracellular vesicles (EVs) that are involved
in numerous pathophysiological processes by removal
and exchange of excess and unwanted RNAs, proteins,
receptors, and metabolites. Recent studies also suggest
that activated cell-derived EVs can help identify early
and late pathophysiological processes and contribute to
the diagnosis, prognostic assessment, and management
of individuals with suspected renal diseases [13,14].
However, a detailed profile of cellular injury or markers
of cellular activation that could elucidate potential
mechanisms involved in stone formation has yet to be
developed.
Therefore, the present study was designed to quantify
and characterize the cellular origin of EVs (Figure 1) in a
24-h urine from first time kidney stone formers and age-
matched persons without a history of kidney stones in
the general population of Olmsted County, MN. Our hy-
potheses were as follows: (1) that the number and types
of urinary EVs would differ between men and women
and between persons with and without kidney stones
and (2) that the nature of these differences may help to
design larger and/or molecular studies to understand
the sex differences in kidney stone disease. Complete
characterization of urinary EVs in kidney stone formers
may lead to identify novel cellular processes associateda membrane and exosomes (~30–100 nm) from multivesicular
viations: PC phosphatidylcholine, SM sphingomyelin, PS
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stratification and identification of early kidney stone or
other renal disease processes, holding the potential to
develop personalized treatment strategies based on the
sex of the person.
Methods
Chemicals, reagents, and antibodies
Recombinant annexin-V and mouse anti-human CD9,
CD54, CD63, and CD106 antibodies conjugated with
fluorescein isothiocyanate (FITC) or R-phycoerythrin
(PE) and TruCOUNT™ (4.2 μm) beads were purchased
from BD Biosciences, San Jose, CA. Fluorescent latex
beads (1 and 2 μm) were purchased from Sigma-Aldrich,
Saint Louis, MO. Fluoresbrite® microparticles (0.2, 0.5, 1,
and 2 μm) were purchased from Polysciences, Inc.,
Warrington, PA. FITC-conjugated mouse anti-human
tissue factor was purchased from American Diagnostica
Inc., Stamford, CT. Mouse anti-human podocalyxin-Alexa
Fluor® 488 was purchased from R&D Systems, Inc.,
Minneapolis, MN. FITC-conjugated rabbit anti-TSG
(tumor susceptibility gene) 101, anti-nephrin, anti-
aquaporin-1, anti-aquaporin-2, and anti-cytokeratin
17 (CK17) antibodies were purchased from Biorbyt,
Cambridge, UK. Rabbit anti-NPHS/Podocin, anti-synapto-
podin, anti-claudin-1, anti-galectin, anti-cytokeratin 8,
ant-Lrp (low-density lipoprotein-related protein 2)/megalin,
anti-OAT4L/URAT1, anti-SLC12A3/NKCC (Na-K-Cl co-
transporters), anti-prominin 2, anti-ATPVOD2/V-ATPase
(vacuolar-type H+-ATPase), anti-CK19, anti-CK20, and
anti-E-cadherin/CD234 polyclonal antibodies conjugated
with FITC or PE were purchased from Bioss, Boston, MA.
PE-conjugated mouse anti-human epidermal growth factor
receptor (EGFR) and anti-human monocyte chemotac-
tic protein-1 (MCP-1) antibodies were purchased from
BioLegend Inc., San Diego, CA. FITC-conjugated mouse
anti-human uromodulin were purchased from LSBio
LifeSpan BioSciences, Inc., Seattle, WA. Mouse anti-human
CD10 (neprilysin) was purchased from eBiosciences, Inc.,
San Diego, CA. 4-(2-Hydroxyethyl)-1-piperazineethanesul-
fonic acid (HEPES) and Hanks’ balanced salts were
purchased from Sigma Chemicals Co., St. Louis, MO.
All other reagents and solvents used in this study were
of analytical/reagent grade.
Study participants
This study was approved by the Institutional Review
Board at Mayo Clinic, Rochester, MN. All participants
gave written informed consent. Urine from randomly
selected study participants of the Mayo Clinic O’Brien
Urology Research Center Olmsted County population of
symptomatic first time kidney stone formers and age-/
sex-matched (19–76 years old) men and women with-
out a history of kidney stones was used in this study.Participants completed study visits that included a struc-
tured questionnaire to obtain demographics, past medical
history, and medical comorbidities.
Urine sample collection and preparation for this study
Two 24-h urine samples 3 months apart were collected
on a free-choice diet using mailed collection materials,
written instructions, and verbal instruction provided by
a study coordinator. Aliquots of 24-h urine samples were
centrifuged at 3,400 rpm for 10 min to remove cells and
larger molecular weight protein aggregates. Fresh or
frozen (−80°C) cell-free urine samples were used in this
study.
Electron microscopy
Fresh or frozen 24-h cell-free urine samples were centri-
fuged at 20,000 g for 30 min to pellet urinary EVs. After
centrifugation, vesicle-free urine was either discarded or
stored at −80°C for other analyses. Pelleted urinary EVs
were washed with HEPES/Hank’s (H/H) buffer pH 7.4
by vortexing for 1–2 min and then centrifuged at the
same speed for 30 min. This supernatant was discarded,
and urinary EVs were examined by transmission electron
microscopic analysis as previously described for periph-
eral blood microvesicle analysis [15]. The heterogeneous
nature of EV size was confirmed by transmission elec-
tron microscopy (Figure 2).
Urine biochemistry
All urine biochemistry measurements in the 24-h
urine were performed in the Mayo Clinic Renal Testing
Laboratory, Rochester, MN, using standard protocols.
Characterization of urinary EVs by flow cytometer
Digital flow cytometry (FACSCanto™) was used to define
EVs by size and annexin-V fluorescence. Gates to define
the size of EVs were set using an internal standard of
0.2, 0.5, 1, and 2 μm Fluoresbrite® microparticles.
Samples were spiked with a known quantity of 4.2μm
diameter TruCOUNT™ (BD Biosciences, San Jose, CA)
beads for quantification (Figure 3A–C). All buffers and
antibodies were filtered twice through a 0.2 μm-sized
membrane filter to eliminate chemical particles and to
reduce instrument noise [15,16]. Acquisition gates for
EVs with and without annexin-V or renal cell-specific
monoclonal/polyclonal antibodies conjugated with fluoro-
phore are shown in the microvesicle gate (Figure 3D–F).
All the settings of flow cytometry were similar to those
previously described for peripheral blood microvesicle
analysis [15,16]. Urinary EVs were defined as events higher
than 0.2 μm and less than 1 μm in diameter that were
positive for annexin-V or cell-specific nephron markers
(Figure 4). A considerable number of EVs greater than
1 μm in diameter were also observed in certain stone
200nm1µm
Figure 2 Representative transmission electron microscopy of urinary EVs isolated by high-speed centrifugation. Arrow heads indicate
membranes; lower (A) and higher (B) magnification of heterogeneous population of urinary EVs.
Figure 3 Representative typical scatter plots (A–C) and fluorescence dot (quadrants) plots (D–F) from FACSCanto™ flow cytometry,
respectively. (A) Control gates of buffer with fluorophore-conjugated antibodies and calibration beads. (B) Gates derived from diluted urine plus
appropriate fluorophore-conjugated antibodies and calibration beads from one individual. (C) Gates derived from diluted urine plus appropriate
fluorophore-conjugated antibodies and calibration beads from another individual. (D) Fluorescent dot plot (quadrants derived from microvesicle gate
of Figure 3B) showing fluorophore spectra separate of annexin-V and P-selectin (activated platelet specific protein, irrelevant antibody control used for
urine EV analysis). A similar pattern was observed with isotype control (fluorophore conjugated IgG) antibodies in diluted urine samples (data not
shown). (E) Fluorescent dot plot (quadrants derived from microvesicle gate of Figure 3B) showing fluorophore spectra separate of annexin-V and CD9
antibody. (F) Fluorescent dot plot (quadrants derived from microvesicle gate of Figure 3B) showing fluorophore spectra separate of annexin-V and
aquaporin-2 (a specific marker for collecting duct cell-derived EVs) fluorophore-positive (+) and fluorophore-negative (−) EVs. Similar fluorescent dot
plots were obtained from diluted urine stained with specific antibodies for cells of the urinary tract (Figure 4, data not shown).



















































Figure 4 Specific markers were used to identify EVs derived from cells of different segments of the nephron and renal pelvis. All indicated
markers were used in this study but only data of EVs positive for one or two markers of each cell type were presented in this manuscript.
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limit for microvesicles was adopted as is standard for the
analysis of peripheral blood [17]. To optimize the concen-
tration and flow rate of urinary EVs for flow cytometric
analysis, urine samples (20 μl) diluted with 80 μl of filtered
H/H buffer pH 7.4 were incubated with 3–5 μl of
annexin-V-fluorescein (FITC) for 30 min. After incuba-
tion, 800 μl of H/H buffer pH 7.4 plus 100 μl containing a
defined quantity of TruCOUNT™ beads (BD Biosciences,
San Jose, CA) was added to each sample tube prior to
analysis by flow cytometer. The flow rate (low, medium,
or high) was determined based on the threshold rate of
events/second from the sample tube. For example, thresh-
old events higher than 1,000 per second reduced the flow
rate to low or medium and always maintained flow rate
medium or low with less than 1,000 events/second. Very
few samples had low threshold events less than 100
events/second, and therefore, the flow rate was increased
to high in only these few samples. Gain settings of the flow
cytometer were adjusted to place the TruCOUNT™ beads
(4.2 μm) in the upper log for scatter. Unfiltered Isoton® II
diluent from Beckman Coulter, Fullerton, CA, was usedin the cytometer. Compensation for channel spill was
calculated using the auto-compensation feature from re-
corded values of separate and combined unstained and
single antibody-stained urinary EVs. Auto-calculated
compensation parameters were verified weekly. Urinary
EVs are defined in this study as events less than 1 μm
(microvesicles) gate and higher than 1 μm in diameter
gate and positive for annexin-V and cell-specific markers
of nephrons (Figures 3 and 4). The thresholds were set
with isotype controls or irrelevant fluorescent antibodies
(Figure 3D). Urinary EVs stained in phosphate-buffered
saline or HEPES-buffered saline (HBS; pH 7.4) without
calcium served as negative controls for annexin-V positivity.
The absolute count of urinary EVs either in the absence or
presence of single or dual fluorescent staining was calcu-
lated with the following previously established method of
calculation for blood microvesicles [15,16]. The volume of
urine (ranging between 5 and 80 μl) was adjusted in the
subsequent experiments in order to have at least 2,500 EVs
in a microvesicle gate that stained positive with annexin-V,
since it binds to phosphatidylserine expressed on the sur-
face of EVs and allows their distinction from chemical
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was expressed as the number of urinary EVs per microliter
of urine and also normalized to urine creatinine concentration.
Standardization and validation of urinary EV analysis
For standardization of urinary EV analysis, cell-free 24-h
fresh and/or frozen urine samples from a mixed population
(controls plus first time kidney stone formers) were used.
Flow cytometry
Inter-individual variability of light scattering (size) was
observed. For example, in one participant, greater than
95% of urinary EVs were less than 1 μm in size (microve-
sicle gate, Figure 3B), but in another, only 60–70% of
EVs fell in the microvesicle gate with the remainder
greater than 1 μm in size (aggregate gate, Figure 3C).
This light-scattering heterogeneity was present across all
sex and stone-forming groups. Therefore, all urinary EV
data are presented for both microvesicle (<1 μm in size)
and aggregate (>1 μm in size) gates. Annexin-V positiv-
ity was verified in 48 urine samples using two fluoro-
phores FITC and PE that revealed a strong correlation
(ρ = 0.71, Figure 5). Quantification of EV origin wasFigure 5 Podocyte markers displaying high intra-individual correlatio
conjugated to annexin-V and binding to surface phosphatidylserine on EVs fr
distinct antibodies for the same cell-specific antigens (e.g., podocytes) binding
annexin-V-positive vesicles did not correlate with urine osmolality. There were
exosome marker (CD63, lower right)-positive EVs between two different 24-hverified in each case using two different protein markers
specific for that nephron segment. Figure 4 depicts
nephron segment-specific markers used to identify the
source of urinary EVs. For example, podocyte-derived
urinary EVs were verified by both nephrin and synaptopo-
din staining. Both of these podocyte markers displayed
high intra-individual correlation (ρ = 0.98, Figure 5). The
number of annexin-V-positive urinary EVs did not correl-
ate with urine osmolality (ρ = −0.14, Figure 5) suggesting
they were independent of urine flow rate. There was no
difference in the concentration of urinary EVs positive for
annexin-V and CD63 in the 24-h urine collection from the
same person when visits 1 and 2 were compared (Figure 5).
Further, the concentration of annexin-V-positive EVs mea-
sured in fresh versus frozen (few weeks to several months)
urine collection of the same individual did not vary signifi-
cantly (data not shown).
Data analysis
Spearman’s correlation was used for comparisons of two
fluorophores and two different protein markers for initial
standardization. Clinical characteristics of study partici-
pants are presented as mean ± standard deviation (SD).n. The upper left is the correlation of two different fluorophores
om the same urine sample. The upper middle is the correlation of two
to urinary EVs from the same urine sample. The upper right shows that
also no differences in the concentration of annexin-V- (lower left) and
urine collections obtained within 3 months from the same individuals.
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were analyzed by analysis of variance (ANOVA) followed
by Student’s t test/Wilcoxon/Kruskal-Wallis (rank sums)
test using JMP software and significance accepted at
P < 0.05. Annexin-V- and exosome marker-positive EVs
of nephron-derived urinary EVs are presented in total and
by nephron/urinary tract segments in Tables 1 and 2 with
median, 25th, and 75th percentiles. Differences in concen-
tration of EVs between control women and men and kid-
ney stone formers were analyzed by ANOVA followed by
Mann-Whitney rank sum test using Sigma plot and/or
Student’s t test/Wilcoxon/Kruskal-Wallis (rank sums) test
using JMP software with significance accepted at P < 0.05.
Results
Clinical characteristics
In general, the groups were comparable. Men with kidney
stones were slightly older than the other three groups and
tended to have a larger body mass index (Table 3).
Overall, serum and urine chemistries were similar among
groups, except for higher serum creatinine values in men
(as expected).
The absolute numbers of urinary EVs were normalized
to 24-h urine creatinine concentration. Similar results
were obtained when urinary EVs were analyzed as a
concentration (per microliter of urine) or normalized to
urine creatinine (per milligram creatinine).
Sex differences in populations of urinary EVs between
control women and men
The total number of urinary EVs positive for the follow-
ing markers were significantly (P < 0.05) greater in
control (non-stone forming) women compared to men:
phosphatidylserine (annexin-V), exosome (CD63) marker,
inflammatory molecules (VCAM1, tissue factor, and
MCP-1), podocin plus galactin-1 (derived from glom-
erular podocytes), claudin-1 (parietal epithelium of
the Bowman’s capsule), urate-anion exchanger (simpleTable 1 Total number of phosphatidylserine, exosome, and in
Controls from the general pop
Women (n = 24) Me
Urinary EV/mg creatinine
Total phosphatidylserine positive 3,181 (1,144, 6,072) 697
Total CD63 (exosome) positive 911 (528, 1,258) 185
Cellular adhesion/inflammatory molecules positive for urinary EV/mg creatini
Total E-cadherin positive 6 (2, 21) 5 (2
Total ICAM-1 positive 184 (106, 320) 160
Total VCAM-1 positive 720 (133, 1,708) 48*
Total tissue factor positive 494 (214, 1,012) 204
Total MCP-1 positive 20 (5, 36) 3* (
Data are presented as median (25th, 75th percentile) × 103/mg creatinine and analy
test. *P < 0.05 between men and women of the same group; †P < 0.05 between concuboidal epithelium of the proximal convoluted tubule),
urea transporter (simple squamous epithelium of the thin
loop of Henle), uromodulin (simple cuboidal epithelium of
the thick loop of Henle), thiazide-sensitive NaCl cotran-
sporter (simple cuboidal epithelium of the distal tubule),
aquaporin-2 and V-ATPase (principal and intercalated
cells of the collecting duct; principle cell data not
shown), cytokeratin 19 (transitional epithelium of the
renal pelvis), and neprilysin (urothelium of the urinary
bladder) (Tables 1 and 2). There were no differences in
numbers of EVs positive for cellular adhesion molecules
(E-cadherin and ICAM-1) between control women and
men (Table 1).Differences in populations of urinary EVs between kidney
stone-forming and control women
The total number of exosome (CD63) marker-positive EVs
was greater in urine of women with kidney stones com-
pared to control women. However, all of the following EVs
were significantly lower (P < 0.05) in women with kidney
stones: VCAM1-positive EVs and EVs derived from glom-
erular podocytes, parietal epithelium of the Bowman’s cap-
sule, simple cuboidal epithelium of the proximal
convoluted tubule, simple squamous epithelium of the
thin loop of Henle, simple cuboidal epithelium of the thick
loop of Henle, simple cuboidal epithelium of the distal tu-
bule, principal and intercalated cells of the collecting duct,
transitional epithelium of the renal pelvis, and the urothe-
lium of the urinary bladder (Tables 1 and 2). There were
no differences in the concentration of E-cadherin, ICAM-
1, tissue factor, and MCP-1-positive EVs between women
with and without kidney stones (Table 1).
Sex differences in populations of urinary EVs between
stone-forming women and men
Exosome (CD63) marker, inflammatory molecule (MCP-1)-
positive EVs, and EVs derived from glomerular podocytesflammatory markers positive for urinary EVs
ulation First time kidney stone formers
n (n = 26–36) Women (n = 24–50) Men (n = 26–60)
* (243, 1,158) 3,068 (1,143, 6,166) 1,416† (515, 3,435)
* (86, 580) 2,308† (525, 5,637) 1,062*† (267, 2,628)
ne
, 9) 7 (2, 17) 4 (2, 9)
(33, 657) 204 (93, 627) 163 (43, 627)
(6, 215) 46† (15, 198) 35 (6, 206)
* (67, 667) 611 (241, 2,063) 421 (115, 1,962)
2, 6) 8 (3, 16) 3* (1, 8)
zed by ANOVA followed by Student’s t test/Wilcoxon/Kruskal-Wallis (rank sums)
trol and stone formers of the same sex.
Table 2 Numbers of urinary EVs from epithelial cells of different segments of nephron and urinary tract
Urinary EV/mg creatinine Controls from general population First time kidney stone formers
Nephron segments Markers Women (n = 24) Men (n = 26) Women (n = 24) Men (n = 26)
Glomerulus Podocin + galectin-1 positive 2,708 (1,037, 4,059) 24* (6, 183) 225† (77, 292) 20* (7, 91)
Bowman’s capsule Claudin-1 positive 96 (51, 322) 11* (8, 26) 11† (4, 17) 14 (6, 35)
Proximal tubule URAT1 positive 367 (195, 1,223) 39* (18, 61) 36† (20, 74) 30 (21, 50)
Thin loop of Henle SLC14A2 positive 182 (76, 544) 5* (3, 23) 11† (6, 18) 9 (4, 50)
Thick loop of Henle Uromodulin positive 21,960 (7,423, 46,782) 1,033* (236, 3,389) 2,652† (482, 5,031) 1,458 (302, 4,558)
Distal tubule SLC12A3 positive 611 (93, 1,459) 28* (14, 48) 24† (8, 50) 15 (7, 42)
Collecting duct V-ATPase positive 57 (11, 220) 16* (7, 23) 12† (5, 46) 11 (4, 30)
Renal pelvis Cytokeratin 19 positive 99 (51, 225) 21* (2, 37) 16† (9, 25) 9 (6, 16)
Urinary bladder Neprilysin positive 2,320 (1,308, 3,170) 222* (112, 427) 243† (121, 382) 252 (126, 593)
Data are presented as median (25th, 75th percentile) × 103/mg creatinine and analyzed by ANOVA followed by Student’s t test/Wilcoxon/Kruskal-Wallis (rank sums)
test. *P < 0.05 between men and women of the same group; †P < 0.05 between control and stone formers of the same sex.
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men compared to stone-forming women (Tables 1
and 2). There were no differences in other population
of urinary EVs between stone-forming men and women
(Tables 1 and 2).Table 3 Clinical characteristics, blood, and urine biochemistry
Controls from the general popula
Women (n = 24) Men
Clinical characteristics
Age (years) 44 ± 12 42 ± 1
Body mass index (kg/m2) 28 ± 7 (n = 22) 28 ± 5
Serum calcium (mg/dL) 9.5 ± 0.5 (n = 23) 9.1 ±
Serum creatinine (mg/dL) 0.70 ± 0.1 (n = 23) 0.96 ±
Serum uric acid (mg/dL) 4.4 ± 1.2 (n = 23) 6.0 ±
Serum phosphate (mg/dL) 3.5 ± 0.5 (n = 23) 3.4 ±
Urine biochemistry
pH 6.3 ± 0.5 6.2 ±
Osmolality (mOsm) 623 ± 272 664 ±
Urine volume (mL/24 h) 1,613 ± 742 1,955
Albumin (mg/24 h) 5 ± 13 1.3 ±
Protein (mg/24 h) 12 ± 16 25 ± 1
Creatinine (mg/24 h) 844 ± 207 1,615
Sodium (mmol/24 h) 108 ± 47 180 ±
Potassium (mmol/24 h) 49 ± 27 77 ± 3
Magnesium (mg/24 h) 108 ± 54 155 ±
Calcium (mg/24 h) 202 ± 81 214 ±
Oxalate (mg/24 h) 22 ± 8.6 29 ± 1
Phosphate (mg/24 h) 645 ± 253 965 ±
Uric acid (mg/24 h) 352 ± 138 599 ±
Citrate (mg/24 h) 646 ± 238 637 ±
Data are presented as mean ± SD and were analyzed by ANOVA followed by Studen
between control and stone formers of the same sex.Differences in populations of urinary EVs between
stone-forming and control men
Total number of phosphatidylserine and exosome (CD63)
marker-positive EVs was significantly (P < 0.05) greater in
stone-forming compared to control men (Table 1). Theof study participants
tion First time kidney stone formers
(n = 36) Women (n = 50) Men (n = 60)
2 41 ± 16 51 ± 14*†
(n = 32) 28 ± 8 (n = 33) 31 ± 7 (n = 36)
1.7 (n = 31) 9.5 ± 0.5 (n = 39) 8.9 ± 2.3 (n = 47)
0.2* (n = 31) 0.73 ± 0.1 (n = 39) 0.98 ± 0.2* (n = 46)
1.2* (n = 31) 4.7 ± 1.0 (n = 39) 6.4 ± 1.4* (n = 47)
0.4 (n = 31) 3.7 ± 0.6† (n = 39) 3.4 ± 0.6* (n = 47)
0.6 6.2 ± 0.5 6.0 ± 0.6
224 539 ± 238 689 ± 214*
± 732 1,864 ± 920 1,675 ± 655
3 4 ± 6 6 ± 8†
9* 25 ± 16† 30 ± 22
± 618* 836 ± 302 1,309 ± 628*†
73* 106 ± 40 146 ± 73*†
1* 40 ± 21 53 ± 27*†
81* 89 ± 43 122 ± 63*†
126 175 ± 98 210 ± 124
5 19 ± 11 24 ± 21
468* 581 ± 236 822 ± 414*
223* 373 ± 160 447 ± 226†
370 526 ± 281 535 ± 314
t’s t test. *P < 0.05 between men and women of the same group; †P < 0.05
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did not differ between stone-forming and control men
(Tables 1 and 2).
Discussion
The pathophysiological functions of urinary EVs in kid-
ney stone formation and their cellular origin and num-
bers in the urine of stone formers and controls have not
been established. In this study, we developed and vali-
dated methods to quantitate larger (higher than 0.2 μm)
urinary EVs from specific nephron segments by digital
flow cytometry. Using this standardized technique, we
found sex differences in urinary EV populations between
men and women who did not have kidney stones and
changes in populations of urinary EV in women with
and without kidney stones. Women with and without
their first episode of symptomatic kidney stones both
shed significantly more CD63-positive EVs (indicative of
exosomes derived from mature endosome) compared to
men, whereas persons of both sexes with renal stones
shed a similar number of annexin-V-positive EVs (indi-
cative of microvesicles derived from plasma membrane).
Urinary EVs with markers of diverse nephron segments
were greater in women without compared to those with
kidney stones and men (both with and without stones).
The observation that women with kidney stones had
urinary EV populations similar to men suggests these
markers may reflect renal pathophysiology that causes
men as a group to be at a higher risk of kidney stones.
Key challenges are to better understand basic cellular
mechanisms involved in kidney stone formation and to
identify novel cellular markers for key pathophysiological
processes during kidney stone formation. Renal cells can
be injured by increased urinary concentrations of litho-
genic molecules (e.g., oxalate) or calcium-containing
crystals [12]. Activated or injured cells release biolo-
gically active EVs (~30 nm to 1,000 nm in diameter;
Figure 1). EVs carry biological signatures that reflect
their state of differentiation, anatomical location, and
function. Growing evidence suggests that EVs in the sys-
temic circulation are involved in numerous pathophysio-
logical processes including cardiovascular disease and
cancer, but their role in kidney stone pathophysiology,
either in the blood or urine, is not established. EV also
participates in the transport of specific cellular signaling
molecules from the parent cell to other cells, which in
turn alter the biological activity of recipient cells. For
example, microvesicles from injured nephrons may pro-
mote differentiation of bone marrow stem/precursor
cells, inducing them to shed progenitor cells or EVs
which might participate in injury processes [18]. How-
ever, because the concentration of EVs in the blood and
urine depends upon their cell of origin and the stimulus
which process triggers their production, populations ofurinary EV may reflect an early or late pathophysiological
process of kidney stone formation. In other words, they
may provide more sensitive and specific markers for the
screening, diagnosis, risk stratification, and monitoring of
pharmacological therapy for individuals with renal disease,
including kidney stones.
Our original hypothesis was that urinary EVs would
differ between controls and stone formers in both sexes.
Indeed, for most populations of urinary EV, control
women formed a unique group and shed a greater amount
than either control men or stone-forming women and
men. Overall, stone disease is more common in men than
women. The current study suggests that the urine EV
composition of stone-forming women is similar to that of
both control and stone-forming men. Given that control
men were similar to stone-forming men, these differences
in urine-borne EV populations seem to reflect underlying
cellular processes that may correlate with stone risk,
rather than a response to ongoing stone formation. How-
ever, the underlying reasons for these sex differences in
urinary EV populations could be more subtle. It is import-
ant to note that the populations of EVs were similar in
stone-forming and control men and that the urine of men
is in general more supersaturated than women in respect
to calcium oxalate. Renal cells can be injured by increased
urinary concentrations of oxalate or calcium-containing
crystals [12]. Interestingly, the kidney stone precursor
lesions called Randall’s plaques are associated with
membrane-bound EVs adherent to collagen; these EVs
were hypothesized to have induced further growth of
more mature plaque along the periphery of the collagen
framework [19]. The origin and ultimate fate of these EVs
within the papillary interstitium remains to be elucidated.
Further characterization of the specific cellular origin, pro-
tein, mRNA, micro RNA, and metabolome content of EV
in the urine of men and women, with and without kidney
stones, is warranted and could identify novel diagnostic
and prognostic markers of diseases of the kidney and
urinary tract, including kidney stones. Overall, further
studies looking at longitudinal cohorts before and after in-
cident stone formation would be necessary to answer this
question.
This study clearly highlights the influence of sex on
the shedding of urinary EV. The reasons at this point
are unclear. It seems likely that hormonal status is im-
portant, either by modifying stone risk and urinary
crystallization or by direct effects on tubular cell physi-
ology and pathophysiology. Animal studies support this
statement as female sex hormones (estrogens) prevent
whereas male sex hormones (testosterones) accelerate
the progression of kidney stone disease [20,21]. A previ-
ous study showed that the total numbers of blood-borne
microvesicles were significantly altered by circulating
estrogen status in younger healthy postmenopausal women
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tions also suggest that blood-borne microvesicles positive
for phosphatidylserine and platelet antigen are greater in
women compared to similar age ranges of apparently
healthy men.
Our study has certain limitations. The participants
were largely white Americans of European ancestry res-
iding in the upper Midwest. Thus, results will need to be
replicated in other ethnic groups and locations. Only
first time stone formers were studied, the vast majority
of whom (~95%) have calcium oxalate stones. Thus,
findings might differ in recurrent stone formers or in
other stone types. However, in this study, we have me-
ticulously validated methods to characterize urinary EV
and demonstrate for the first time systematic differences
between men and women and between stone formers
and controls.
Conclusions
Women in the general population shed a significantly
greater number of EVs than men, whereas both stone-
forming women and men shed a similar number of most
populations of urinary EVs from diverse locations along
the urinary tract. These results suggest that women
stone formers have urinary EV similar to those in male
urine and thus urinary EV shedding may mediate or re-
flect sex differences in stone pathogenesis. This study
also suggests further characterization of the specific cel-
lular origin, protein, mRNA, micro RNA, and metabo-
lome content of EVs in the urine of stone formers and
controls is warranted and could identify novel diagnostic
and prognostic cellular markers of kidney stones and
other diseases of the urinary tract.
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